Bryonia, a well-known medicinal plant used mainly in homeopathy as an antiinflammatory, has never been considered an adaptogen. However, much evidence has been accumulated during the last decade indicating that Bryonia roots have adaptogenic properties. This review summarizes the reports (published mainly in Russian) on the chemical composition, the pharmacological and biochemical investigations of the active principles of Bryonia alba roots. It also summarizes reports on clinical trials of a Bryonia extract (tablets prepared from a standardized powder of Bryonia alba root, called "Loshtak" in Armenia) that indicates it is an adaptogenic and restorative drug with immunomodulatory, stress-protective and tonic properties that increase the nonspecific resistance of an organism toward harmful stimuli. The major active components of the Bryonia extract are cucurbitacin glucosides and trihydroxyoctadecadienoic acids (THODA). The biological activities of these compounds are associated with biosynthesis of eicosanoids and corticosteroids, which are important mediators in the immune, endocrine and nervous systems. Clinical trials show that the Bryonia extract was effective in treating workers at the Chernobyl Nuclear reactor who suffered from vegetovessel dystonia and other accompanying illnesses as a result of that facility's well-known accident. It was also effective in preventing radiation-induced disorders and cytostatic side effects in cancer therapy. The use of Bryonia extract in healthy athletes increases their endurance, working capacity and heart rate restoration after physical loading. No side effects caused by Bryonia extract intake were recorded during these trials.